Market Newsdesk

LOS ANGELES, Dec. 17, 2020 /PRNewswire/ — Live Nation Entertainment, Inc. (NYSE: LYV) (the “company”) announced that it intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of senior secured notes due 2028 (the “Notes”).  Obligations under the Notes will be guaranteed by the company and the company’s existing and future domestic restricted subsidiaries that guarantee the company’s senior secured credit facility.

The Notes and the related guarantees will be secured by first-priority liens on substantially all of the company’s and the guarantors’ assets, and such liens and the related guarantees will be equal and ratable with the indebtedness under the company’s senior secured credit facility and 6.500% Senior Secured Notes due 2027.

The company intends to use the net proceeds from the offering to repay $75 million aggregate principal amount of the company’s senior secured term loan B facility, for general corporate purposes, including acquisitions and organic investment opportunities, and to pay fees and expenses related to the offering. Completion of the offering of the Notes is subject to, among other things, pricing and market conditions.

The Notes and the related note guarantees will be offered through a private placement and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. As a result, the Notes and the related note guarantees may not be offered or sold in the United States or to any “U.S. persons” except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Notes and the related note guarantees will be offered only to “qualified institutional buyers” under Rule 144A of the Securities Act and, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This news release is neither an offer to sell nor a solicitation of an offer to buy the Notes, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward-Looking Statements
This news release contains forward-looking statements, including statements related to the offering and the expected use of the net proceeds, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, without limitation, risks related to whether the company will consummate the offering of the Notes on the expected terms, or at all, market and other general economic conditions, and the fact that the company’s management will have discretion in the use of the proceeds from any sale of the Notes. The company refers you to the documents it files with the Securities and Exchange Commission, specifically the section titled “Item 1A. Risk Factors” of its Annual Report on Form 10-K for the year ended December 31, 2019 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, which contains and identifies important factors that could cause actual results to differ materially from those contained in the company’s projections or forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Based upon changing conditions, should any risk or uncertainty that has already materialized, such as, for example, the risks and uncertainties posed by the global COVID-19 pandemic, worsen in scope, impact or duration, or should one or more of the currently unrealized risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described in any forward-looking statements. The company undertakes no obligation to update any forward-looking statement, whether as a result of changes in underlying factors, new information, future events or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/live-nation-entertainment-announces-launch-of-private-senior-secured-notes-offering-301195019.html

SOURCE Live Nation Entertainment

DENVER, Dec. 17, 2020 /PRNewswire/ — Antero Resources Corporation (NYSE: AR) (“Antero Resources”) announced today that, subject to market conditions, it intends to offer $500 million in aggregate principal amount of senior unsecured notes due 2026 (the “Notes”) in a private placement to eligible purchasers.

Antero Resources intends to use a portion of the net proceeds from the offering to fund the redemption of $350 million aggregate principal amount of its 5.125% senior notes due 2022 (the “2022 Notes”) at par plus accrued interest and to use the remaining net proceeds to repay borrowings under its credit facility. The partial redemption of the 2022 Notes is expected to be conditioned on the completion of the offering of the Notes. The offering of the Notes is not contingent upon the completion of such redemption.

The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Notes will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States pursuant to Regulation S under the Securities Act.

This press release is neither an offer to sell nor a solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer to sell or a solicitation of an offer to buy, or a sale of, the Notes or any other securities in any jurisdiction in which such offer, solicitation or sale is unlawful. This press release shall not constitute a notice of redemption of the 2022 Notes.

Antero Resources is an independent natural gas and natural gas liquids company engaged in the acquisition, development and production of unconventional properties located in the Appalachian Basin in West Virginia and Ohio. In conjunction with its affiliate, Antero Midstream (NYSE: AM), Antero is one of the most integrated natural gas producers in the U.S.

This release includes “forward-looking statements.” Such forward-looking statements are subject to a number of risks and uncertainties, many of which are not under Antero Resources’ control. All statements, except for statements of historical fact, made in this release regarding activities, events or developments Antero Resources expects, believes or anticipates will or may occur in the future, such as statements regarding the proposed offering and the intended use of proceeds, including to fund the partial redemption of the 2022 Notes, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934. All forward-looking statements speak only as of the date of this release. Although Antero Resources believes that the plans, intentions and expectations reflected in or suggested by the forward-looking statements are reasonable, there is no assurance that these plans, intentions or expectations will be achieved. Therefore, actual outcomes and results could materially differ from what is expressed, implied or forecast in such statements. Except as required by law, Antero Resources expressly disclaims any obligation to and does not intend to publicly update or revise any forward-looking statements.

Antero Resources cautions you that these forward-looking statements are subject to all of the risks and uncertainties, incident to the exploration for and development, production, gathering and sale of natural gas, NGLs and oil most of which are difficult to predict and many of which are beyond the Antero Resources’ control. These risks include, but are not limited to, commodity price volatility, inflation, lack of availability of drilling and production equipment and services, environmental risks, drilling and other operating risks, regulatory changes, the uncertainty inherent in estimating natural gas and oil reserves and in projecting future rates of production, cash flows and access to capital, the timing of development expenditures, impacts of world health events, including the COVID-19 pandemic, potential shut-ins of production due to lack of downstream demand or storage capacity, and the other risks described under the heading “Item 1A. Risk Factors” in Antero Resources’ Annual Report on Form 10-K for the year ended December 31, 2019 and in its subsequently filed Quarterly Reports on Form 10-Q.

View original content to download multimedia:http://www.prnewswire.com/news-releases/antero-resources-announces-launch-of-500-million-offering-of-senior-notes-301195014.html

SOURCE Antero Resources Corporation

SHANGHAI, Dec. 17, 2020 /PRNewswire/ – Ossen Innovation Co., Ltd. (the “Company“) (Nasdaq: OSN), a China-based manufacturer of an array of plain surface, rare earth and zinc coated pre-stressed steel materials, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement“) with New Ossen Group Limited, an exempted company with limited liability incorporated under the Law of the British Virgin Islands (the “Parent“), and New Ossen Innovation Limited, an exempted company with limited liability incorporated under the Law of the British Virgin Islands and a wholly-owned Subsidiary of Parent (“Merger Sub“), pursuant to which the Parent will acquire the Company for US$1.70 in cash per ordinary share of the Company (the “Shares“), or US$5.10 in cash per American Depositary Share of the Company (each, an “ADS“, representing three Shares).

Subject to the terms and conditions of the Merger Agreement, at the effective time of the merger (the “Effective Time“), Merger Sub will merge with and into the Company, with the Company surviving the Merger as the surviving company and becoming a wholly-owned subsidiary of Parent (the “Merger“). At the Effective Time, each of the Company’s ordinary shares issued, outstanding and not represented by ADS immediately prior to the Effective Time, other than the Excluded Shares and the Dissenting Shares (each as defined in the Merger Agreement), will be cancelled and cease to exist in exchange for the right to receive US$1.70 in cash and without interest, and each ADS of the Company, other than ADSs representing the Excluded Shares, together with each Share represented by such ADSs,  will be cancelled in exchange for the right to receive US$5.10 in cash without interest.

Pujiang International Group Limited (the “Sponsor“) has entered into an equity commitment letter with the Parent, pursuant to which the Sponsor committed to invest in the Parent at or immediately prior to the Effective Time an aggregate cash amount equal to US$12.5 million. The Sponsor has entered into a limited guarantee in favor of the Company in respect of certain payment obligations of Parent under the Merger Agreement.

The Company’s board of directors (the “Board“), acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee“), approved the Merger Agreement and the Merger and resolved to recommend that the Company’s shareholders vote to authorize and approve the Merger Agreement and the Merger. The Special Committee negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.

The Merger, which is currently expected to close during the first half of 2021, is subject to customary closing conditions including the approval of the Merger Agreement by an affirmative vote of holders of Shares representing at least a majority of the Shares present and voting in person or by proxy at a meeting of the Company’s shareholders which will be convened to consider the approval of the Merger Agreement and the Merger. Pujiang International Group Limited, which is controlled by Mr. Liang Tang, has agreed to vote all of the Shares they beneficially own, which represent approximately 65.9% of the voting rights attached to the outstanding Shares as of the date of the Merger Agreement, in favor of the authorization and approval of the Merger Agreement and the Merger. If completed, the Merger will result in the Company becoming a privately-held company and its ADSs will no longer be listed on the Nasdaq Capital Market.

Houlihan Lokey (China) Limited is serving as the financial advisor to the Special Committee. DLA Piper LLP is serving as the U.S. legal counsel to the Special Committee. Ogier is serving as British Virgin Islands legal counsel to the Special Committee. Becker & Poliakoff, LLP is serving as the U.S. legal counsel to the Company. Wilson Sonsini Goodrich & Rosati is serving as the U.S. legal counsel to Parent and the Sponsor. 

Additional Information About the Merger

The Company will furnish to the U.S. Securities and Exchange Commission (the “SEC”) a current report on Form 6-K regarding the Merger, which will include as an exhibit thereto the Merger Agreement. All parties desiring details regarding the Merger are urged to review these documents, which will be available at the SEC’s website (http://www.sec.gov).

In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the “Schedule 13E-3”). The Schedule 13E-3 will be filed with the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE SCHEDULE 13E-3 AND OTHER MATERIALS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE MERGER, AND RELATED MATTERS. In addition to receiving the Schedule 13E-3 by mail, shareholders also will be able to obtain these documents, as well as other filings containing information about the Company, the Merger, and related matters, without charge from the SEC’s website (http://www.sec.gov).

About Ossen Innovation Co., Ltd.

Ossen Innovation Co., Ltd. manufactures and sells a wide variety of plain surface pre-stressed steel materials and rare earth coated and zinc coated pre-stressed steel materials. The Company’s products are mainly used in the construction of bridges, as well as in highways and other infrastructure projects. The Company has two manufacturing facilities located in Maanshan, Anhui Province, and Jiujiang, Jiangxi Province.

Safe Harbor Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s annual report on Form 20-F. All information provided in this press release is as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

For more information, please contact:

Wei Hua, Chief Executive Officer
Email: [email protected]
Phone: +86-21-6888-8886
Web: www.osseninnovation.com

Investor Relations
GCI IR
Phone: +1-347-393-4230
Email: [email protected]

View original content:http://www.prnewswire.com/news-releases/ossen-innovation-enters-into-definitive-merger-agreement-for-going-private-transaction-301195013.html

SOURCE Ossen Innovation Co., Ltd.

GOTHENBURG, Sweden, Dec. 17, 2020 /PRNewswire/ — Castellum has signed a 25-year leasing agreement with the Swedish Migration Agency for an area of approximately 5,600 sq.m. with a total annual average rental value of approximately SEK 24 million.

During the spring, remodeling and adjustments of one of Castellum’s existing properties in Mölndal will start for the tenant, the Swedish Migration Agency. The project will begin in the spring of 2021 and is expected to be completed during the summer of 2022.

Facts and figures in brief:

• Tenant: The Swedish Migration Agency
• Area: 5,600 sqm
• Investment rebuilding / adjustments: SEK 272 million
• Total rental value over 25 years (including adjustments): approximately SEK 600 million, corresponding to an annual average rental value of approximately SEK 24 million.

For further information please contact:

Ulrika Danielsson, CFO Castellum AB, +46 706 47 12 61

About Castellum:

Castellum is one of Sweden’s largest listed real estate companies with a property value of SEK 98 billion. We are active in 17 Swedish growth regions as well as in Copenhagen and Helsinki. Every day, 250,000 people go to work in our premises. We develop flexible workplaces and logistics solutions in close proximity to city centres and with a lettable area of 4.3 million square meters. One of our sustainability goals is to be completely climate neutral by 2030. Castellum is the only Nordic real estate company selected by the Dow Jones Sustainability Index (DJSI). The Castellum share is listed on the Nasdaq Stockholm Large Cap.

Beyond expectations.

www.castellum.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/castellum/r/castellum-signs-a-25-year-leasing-agreement-with-the-swedish-migration-agency,c3256173

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/castellum-signs-a-25-year-leasing-agreement-with-the-swedish-migration-agency-301194994.html

SOURCE Castellum

SANDVIKEN, Sweden, Dec. 17, 2020 /PRNewswire/ — Sandvik will publish its fourth quarter results on Thursday, 21 January 2021 at approximately 08.00 CET.

A combined webcast and conference call for investors, analysts and financial media will be held at 10.00 CET.

The report will be presented in a webcast and conference call by Stefan Widing, President and CEO as well as by Tomas Eliasson, CFO.

The presentation will be broadcasted live on our website home.sandvik

Dial-in details for the conference call:

SE: +46 (0) 8 505 583 69
UK: +44 (0) 333 300 92 60
US: +1 833 526 8398

From about 09.00 CET presentation slides will be available on our website home.sandvik

For further information, contact Louise Tjeder, Vice President Investor Relations, phone: +46 70 782 6374 or Martin Blomgren, Press and Media Relations Manager, phone: +46 70 577 0549.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sandvik/r/invitation—presentation-of-sandvik-s-report-of-the-fourth-quarter-2020,c3257123

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/invitation—presentation-of-sandviks-report-of-the-fourth-quarter-2020-301194991.html

SOURCE Sandvik

MONMOUTH JUNCTION, N.J., Dec. 17, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the promotion of Dr. Christian Steiner to Executive Vice President – Sales and Marketing of CytoSorbents Corporation, effective immediately.  Dr. Steiner will continue as Co-Managing Director of CytoSorbents Europe GmbH, and its subsidiaries.

Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, “I am pleased to have this opportunity to publicly recognize Christian’s great contributions to CytoSorbents over the more than 9 years we have been working together.  Christian has been instrumental in building the CytoSorb business from the very beginning, establishing an initially unknown therapy to now a market leader in our field that has generated more than $100 million in cumulative sales.  He has led the growth and management of CytoSorbents Europe GmbH as Co-Managing Director, building a world-class commercialization team that has resulted in a solid multi-year history of increasing CytoSorb adoption, published data, and sales growth.  Christian combines a strong science and medical understanding with more than 20 years of sales and marketing experience introducing innovative medical devices to the critical care market.  As a key member of our corporate management team who has coordinated the commercialization of CytoSorb, Christian is a visionary that excels at strategy, critical thinking, problem solving, organization, and execution with more contributions to the company than can be counted.  On behalf of the Board of Directors and the management team, we thank Christian for a job well-done, congratulate him on this well-deserved promotion, and look forward to even greater levels of future success.”

Dr. Christian Steiner stated, “At the first meeting with Phil and Vince in Berlin many years ago, I already felt that CytoSorb had the potential to save thousands, and perhaps even millions of lives one day.  It is such a strikingly simple yet powerful technology that gets to the core of the deadly systemic inflammation that kills patients in the ICU.  I exactly remember how we first established our commercialization subsidiary, the first hires, the first medical conferences, the first published clinical data, the first commercial sales, and the excitement and surprise from pioneering doctors who performed the first CytoSorb treatments.  Now with more than 60,000 patients treated and more than 110,000 treatments delivered to date in more than 66 countries worldwide, I am as passionate and convinced as ever that this disruptive therapy is helping to save lives and is going to change medicine.”

Dr. Steiner continued, “It has been amazing to help drive CytoSorbents’ growth, with today more than 90 people in Europe and nearly 100 employees in the United States.  I am particularly proud of how our dedicated teams worked together during this current pandemic to make our therapy available to patients all over the word who were suffering from critical illnesses like COVID-19, septic shock, and liver failure, or who required cardiac surgery.  Coming off of a record third quarter, on an annualized revenue run rate of more than $40 million, I look forward with tremendous optimism and am very grateful for this opportunity to be part of writing medical history.  I thank my management colleagues and the Board of Directors, our dedicated team that shares an unshakable will to change the status quo, the many clinicians and researchers who have put their trust in CytoSorb and pioneered its role across many applications, and finally all of our investors who have made, and still make, the introduction and commercialization of this therapy possible.”

About CytoSorbents Corporation (

NASDAQ: CTSO

)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 110,000 human treatments to date.  CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery.  CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.  CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K⁺ontrol™, ContrastSorb, DrugSorb, and others.    For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, including statements regarding our expectations about our cash runway, the advancement of our trials, our plans to initiate new trials, our goals to develop and commercialize CytoSorb and the timing thereof, the potential impact of COVID-19 on our operations and milestones,  and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on

Facebook

 and

Twitter

Cytosorbents Contact:

Amy Vogel

Investor Relations
732-398-5394
[email protected]

Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors
917-749-1494
[email protected]

Public Relations Contact:

Eric Kim

Rubenstein Public Relations
212-805-3055
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-promotes-dr-christian-steiner-to-executive-vice-president-of-sales-and-marketing-301194891.html

SOURCE CytoSorbents Corporation

SECAUCUS, N.J., Dec. 17, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and The Commons Project, a non-profit public trust dedicated to building and operating global digital platforms and services for public good, today announced a collaboration that will give individuals more control over how and when they can access their data.

With the new collaboration, Quest Diagnostics also joins a handful of industry members of the Commons Project Foundation, which is focused on enabling people to access digital versions of their COVID-19 test results and vaccination records in order to more safely open international borders and resume economic activity.

Through the new collaboration, individuals can elect to access their Quest Diagnostics laboratory testing data through CommonHealth, the privacy-preserving Android app. The solution makes it easier for patients to access and review all their health data on a single, secure app.

“As patients navigate their health during the pandemic, and beyond, it is more important than ever to have their health data in one place,” said Cathy Doherty, Senior Vice President and Group Executive, Clinical Franchise Solutions and Marketing for Quest Diagnostics. “By making Quest Diagnostics lab results accessible via CommonHealth, more individuals will have convenient access to their most critical and up-to-date health information, for better health decisions powered by diagnostic insights.”

Approximately 55 percent of people in the United States are Android users. CommonHealth – available as a free download via Google Play – is the first and the only platform designed to allow users of the Android operating system to manage their medical records on Android-enabled devices and smartphones.

“As we expand our network with digital solutions that help people better manage their health, we need trusted members to help provide secure lab results and vaccination data in a timely and accurate way,” said Dr. Brad Perkins, CMO, The Commons Project. “Our collaboration with Quest unlocks access to the world’s largest database of clinical lab results for more than half the population that uses Android devices, putting them in control of their private health data.”

CommonHealth aggregates health information, such as lab test results and vaccine information, from more than 320 U.S. hospitals and allows users to download, store, manage and share with other apps and services they trust. In doing so, Quest Diagnostics and The Commons Project intend to accelerate a shared vision to improve people’s lives by giving them greater insight and control over their health data.

Quest’s Commitment to Consumer Empowered Health

Quest Diagnostics has long been at the forefront of the movement for consumer empowerment in healthcare. The company was among the first diagnostic information services providers to offer free access to test results online and other channels. Its mobile app and patient portal, called MyQuest, provides its more than 14 million users a way to securely access and track their test results and other health data. The company’s QuestDirect service provides dozens of tests for conditions ranging from heart health and sexually transmitted diseases. For added convenience, the company now offers at-home self-collection devices for tests including COVID-19 infection, diabetes, and hormones. Through its collaborations with Safeway and Walmart, Quest Diagnostics operates approximately 200 patient service centers in retail store locations, for the utmost in convenient access. Quest Diagnostics also provides next-generation sequencing and genotyping services for Ancestry.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com 

About The Commons Project
The Commons Project is a non-profit public trust building global digital services and platforms for the common good. Founded with support from the Rockefeller Foundation and based in Switzerland, it was established to build and operate the shared platforms and services that neither governments nor tech companies are well-positioned to create. The Commons Project’s public trust governance structure is designed to ensure that people’s interests are served above all. Learn more at thecommonsproject.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-and-the-commons-project-to-deliver-convenient-access-to-lab-data—-including-covid-19-test-results—-through-the-commonhealth-app-301194550.html

SOURCE Quest Diagnostics

RACINE, Wis., Dec. 17, 2020 /PRNewswire/ — Modine Manufacturing Company (NYSE: MOD), a leader in technology in the HVAC industry, has announced a new Modine Control System (MCS) option for their line of Indoor Separated Combustion Heating and Make-Up Air units.

Equipped with a 32-bit microprocessor for fast processing speed, the MCS Carel pCOOEM+ programmable controller features a number of I/O’s for complex HVAC/R applications. The controller is fully configured at the factory for the customer’s preferred application settings to make job-site startup and commissioning easier.

“With this new control system, Modine has addressed the increasing demand for building management system integration,” said Mike Schires, senior product manager for Modine. “Using optional boards, the MCS can interface via many of the most commonly-used serial communication standards. It is already a popular selection on the outdoor units that were released earlier this year.” 

The new control system comes with several benefits including:

• A wide range of damper, supply fan and temperature control strategies to handle a vast array of applications;
• Real-time display of operating characteristics, run-time logging, and alarm notification with a snapshot of unit sensors to greatly improve maintenance and unit diagnosis;
• Real-time clock with scheduler to create custom operating schedules, including up to seven periods per day and either on/off or occupied/unoccupied controls;
• User level and service level screens with individual password protection to provide flexible access to control settings based on user type.

“The Modine Control System can be more cost effective than other options and can accomplish the control sequences without additional discrete components,” said Schires. “The new system also has a simple user interface mounted on the unit with easy-to-understand menus.”

About Modine
Modine, with fiscal 2020 revenues of $2.0 billion, specializes in thermal management systems and components, bringing highly engineered heating and cooling components, original equipment products, and systems to diversified global markets through its four complementary segments: CIS; BHVAC; HDE; and Automotive. Modine is a global company headquartered in Racine, Wisconsin (USA), with operations in North America, South America, Europe and Asia. For more information about Modine, visit www.modine.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/modine-announces-new-control-system-option-for-indoor-separated-combustion-heating-and-make-up-air-systems-301194944.html

SOURCE Modine Manufacturing Company